Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

103.22 Organization Policy on Institutional Biosafety Committee (IBC) and the JHM IRB

August 2013

The Organization requires that certain human subjects research studies by reviewed and approved by the Institutional Biosafety Committee (IBC).  These studies include those in which investigators wish to introduce recombinant or synthetic nucleic acid molecules (DNA/RNA), potentially infectious agents or pathogens, or biological toxins into human subjects.  IBC approval of such research must precede approval for conduct by a JHM IRB. 

Additionally, the Organization requires that individuals who collect and/or ship biological specimens register with the Biosafety Office.  For the purposes of human subjects research, this requirement extends to studies conducted at the Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center only.  Investigators must document satisfaction of this requirement in the eIRB application prior to final approval by a JHM IRB. 


AAHRPP

 

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer